{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:18:46Z","timestamp":1762899526872,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clgc.2018.01.016","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T12:51:09Z","timestamp":1517835069000},"page":"e735-e742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Raffaele","family":"Ratta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-2768","authenticated-orcid":false,"given":"Paolo","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-0743","authenticated-orcid":false,"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-2253","authenticated-orcid":false,"given":"Giovanni","family":"Fuc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.01.016_bib1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.01.016_bib2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/DDDT.S104225","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy","volume":"10","author":"Grassi","year":"2016","journal-title":"Drug Des Devel Ther"},{"year":"2013","series-title":"SEER Cancer Statistics Review, 1975-2010","author":"Howlader","key":"10.1016\/j.clgc.2018.01.016_bib3"},{"key":"10.1016\/j.clgc.2018.01.016_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie","volume":"338","author":"Negrier","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.01.016_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2016.06.012","article-title":"Immunotherapy advances in uro-genital malignancies","volume":"105","author":"Ratta","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2018.01.016_bib7","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell\u00a0carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.01.016_bib9","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.01.016_bib12","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.01.016_bib13","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.01.016_bib14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.01.016_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2014.04.006","article-title":"A\u00a0systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer","volume":"67","author":"Albiges","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.01.016_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clgc.2018.01.016_bib17","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib18","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s11255-017-1703-y","article-title":"Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era","volume":"49","author":"Marchioni","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2018.01.016_bib19","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1200\/JOP.2013.001180","article-title":"Real-world outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic Registry","volume":"10","author":"Harrison","year":"2014","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2018.01.016_bib20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/annonc\/mdq651","article-title":"Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings","volume":"22","author":"Beck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5301\/tj.5000581","article-title":"Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy","volume":"103","author":"Mennitto","year":"2017","journal-title":"Tumori"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2018.01.016_bib22","first-page":"v605","article-title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)","volume":"28","author":"Bex","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/annonc\/mdv504","article-title":"Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry","volume":"27","author":"Wagstaff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.01.016_bib24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis","volume":"26","author":"Bracarda","year":"2015","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:47Z","timestamp":1761564527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318300752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1558767318300752"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.01.016","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}